Axis Therapeutics is a leading immunotherapy company focused on the development of TCR (T-cell receptor) therapies to fight cancer.
The Company is developing a new class of innovative TCR therapies can harness the immune system to recognize and destroy cancerous cells in more patients, more effectively.
Through the TCR-T technology platform, the Company has generated engineered T-cells with higher binding affinity, specificity, express level and persistence. Preliminary studies have shown positive clinical signals.
We believe our TCR-Ts will be able to target a broad range cancers, especially solid tumors, and provide patients with long term effective cancer control without the need for sustained supportive care.